TOP > 外国特許検索 > NUCLEIC ACID CONSTRUCT, MEDICINAL COMPOSITION, ANTICANCER AGENT, ANTIVIRAL AGENT AND ANTIBACTERIAL AGENT

NUCLEIC ACID CONSTRUCT, MEDICINAL COMPOSITION, ANTICANCER AGENT, ANTIVIRAL AGENT AND ANTIBACTERIAL AGENT NEW

外国特許コード F190009995
整理番号 (S2018-0489-N0)
掲載日 2019年10月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP014183
国際公開番号 WO 2019189827
国際出願日 平成31年3月29日(2019.3.29)
国際公開日 令和元年10月3日(2019.10.3)
優先権データ
  • 特願2018-067565 (2018.3.30) JP
発明の名称 (英語) NUCLEIC ACID CONSTRUCT, MEDICINAL COMPOSITION, ANTICANCER AGENT, ANTIVIRAL AGENT AND ANTIBACTERIAL AGENT NEW
発明の概要(英語) Provided is a nucleic acid construct that comprises at least one kind of guide RNA part capable of binding to one or more target RNAs and an RNA cleavage Cas protein expressing part, wherein the target RNA(s) are derived from a mutation in a vertebrate cell, a virus or a bacterium.
従来技術、競合技術の概要(英語) BACKGROUND ART
Genome editing is, as the CR7ISPR/Cas9 system, a number of applications have been known. Genome editing, CRISPR/Cas9 enzyme, or an expression construct encoding, the guide with the nucleic acid, the delivery target cell at the same time is implemented. Genome editing of therapeutic applications, a disadvantage of large side effects (non-patent document 1) is.
RNA genome editing to be edited and other known, non-patent document 2, 3 is, as the enzyme RNA editing, C2C2/Cas13 has been disclosed.
In treating cancer, cell 2000's mRNA expression control attempt from the beginning of the siRNA, shRNA (non-patent document 4, 5) have been used. Proteins in the basic research in the art is a significant impact on the control of gene expression have been provided, including the treatment of cancer treatment in a clinical field, an effective method of use are not found in the diagnosis. This is, siRNA, shRNA nucleic acid RNA-molecule is constituted by only, of the selected narrow target gene, the target therapy effects on to a sufficient flexibility due to not.
With respect to the infection, the anti-viral agent, the antimicrobial agent is developed, the problem of resistance by the use of these agents is generated.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • 発明者(英語)
  • ITOH, Tatsuo
  • OGINO, Keiki
  • SUJI, Mika
  • BANDARU, Srinivas
  • SHIMIZU, Yurika
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close